TITLE: Addition of Tocilizumab to standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis

Short title: Tocilizumab in the treatment of severe COVID-19

Authors: Umesha Boregowda,[1] Abhilash Perisetti,[2] Arpitha Nanjappa,[3] Mahesh Gajendran,[4] Hemant Goyal.[5]

Affiliations:

1. Umesha Boregowda, MD
   Department of Medicine,
   Bassett Medical Center,
   1 Atwell Road,
   Cooperstown NY 13326,
   Office: 607-547-4586
   Email: umeshanb007@gmail.com

2. Abhilash Perisetti, MD, FACP
   Department of Gastroenterology and Hepatology
   University of Arkansas for Medical Sciences,
   Little Rock, AR, USA
   Email: abhilash.perisetti@gmail.com

3. Arpitha Nanjappa, MD
   Department of Medicine,
   Bassett Medical Center,

1 Atwell Road,

Cooperstown NY 13326,

Office: 607-547-4586

Email: arpitha.kamalananjappa@bassett.org

4. Mahesh Gajendran, MD, MPH, FACP

Department of Internal Medicine,

Texas Tech University, Paul L Foster School of Medicine,

El Paso, Texas 79905, United States.

Phone number: 915-215-8000

Fax Number: 915-612-9254

Email: Mahesh.Gajendran@ttuhsc.edu

5. Hemant Goyal, MD, MD FACP PGDCA (MBA)

The Wright Center for Graduate Medical Education

501 S. Washington Avenue

Scranton, PA 18503

Office: 570-591-5175

Email: doc.hemant@yahoo.com

Contributions:

Conception and design: Umesha Boregowda, Hemant Goyal

Literature review: All authors

Drafting manuscript: Umesha Boregowda, Kamala Nanjappa, Mahesh Gajendran

Critical revision and editing: All authors

Final approval: All authors

Funding: There was no funding for this research

Declarations of interest: None

Word count: 2,666 excluding abstract, tables, figures, and references

Figures: 4+ Supplementary figure 1

Tables: 2+ Supplementary Table 1

Corresponding author:

Umesha Boregowda, MD

Department of Medicine,

Bassett Medical Center,

1 Atwell Road,

Cooperstown NY 13326,

Office: 607-547-4586

Email: umeshanb007@gmail.com

ABSTRACT:

Introduction:

Tocilizumab is an anti-interleukin-6 antibody that has been used for the treatment of severe coronavirus disease 2019 (COVID-19). However, the concrete evidence of its benefit in reducing the mortality in severe COVID-19 is lacking. Therefore, we performed a systematic review and meta-analysis of relevant studies that compared the efficacy of Tocilizumab in severe COVID-19 vs. standard of care alone.

Methods: Literature search for studies that compared 'Tocilizumab' and 'Standard of care' in the treatment of COVID-19 was done using major online databases from December 2019 to June 14th, 2020. Search words ' Tocilizumab,' 'anti-interleukin-6 antibody,' and 'COVID-19' or 'coronavirus 2019' in various combinations were used. Articles in the form of abstracts, letters without original data, case reports, and reviews were excluded. Data was gathered on an excel sheet, and statistical analysis was performed using Review Manager 5.3.

Results:

Five studies were eligible from 693 initial studies, including 3,641 patients (>2283 males). There were thirteen retrospective studies and three prospective studies. There were 2,488 patients in the standard of care group and 1,153 patients in the Tocilizumab group. The death rate in the tocilizumab group, 22.4% (258/1153), was lower than the standard of care group, 26.21% (652/2,488) (Pooled odds ratio 0.57 [95% CI 0.36-0.92] p=0.02). There was a significant heterogeneity (Inconsistency index= 80%) among the included studies.

Conclusion:

The addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19. Larger randomized clinical trials are needed to validate these findings.

Keywords: SARS Cov-2; COVID-19; Tocilizumab; Anti-interleukin 6 monoclonal antibody; mortality

Abbreviations:

COVID 19: coronavirus disease 2019

SARS: Severe Acute Respiratory Syndrome

SARS-CoV-2: Severe acute respiratory syndrome coronavirus -2

ARDS: Acute respiratory distress syndrome

OR: Odds ratio

I_2: Inconsistency index

TCZ: Tocilizumab

SOC: Standard of care

RCT: Randomized controlled trials

G-CSF: Granulocyte stimulating factor

MCP-1: Monocyte chemoattractant protein 1,

TNF: Tumor necrosis factor

ACE2: Angiotensin-converting enzymes 2

CRS: Cytokine release syndrome

SD: Standard Deviation

CKD: Chronic Kidney Disease

NA: Not applicable

COPD: Chronic Obstructive Pulmonary Disease

TCZ: Tocilizumab

H: Hydroxychloroquine

L/R: Lopinavir/Ritonavir

R*: Ribavirin

R: Remdesivir

O: Oseltamivir

S: Spike protein

INTRODUCTION:

Coronavirus Disease 2019 (COVID-19) is a viral disease caused by Severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) that originated from Wuhan city of Hubei province in China in December 2019.[1, 2] COVID-19 has spread around the world affecting more than 9 million people with more than 473,000 deaths globally.[3] About 6-10% of COVID-19 patients develop acute respiratory distress syndrome (ARDS) with a high mortality rate.[4, 5] The virus commonly spreads through droplets. However, the virus has also been found in gastrointestinal secretions.[6-8] Therefore, potentially the virus transmission could happen through the fecal-oral route as well. Common clinical symptoms of COVID-19 include fever, cough, malaise, shortness of breath, and fatigue.[9] Gastrointestinal manifestations such as diarrhea, and abnormal liver chemistries have also been observed.[10, 11] Laboratory abnormalities in COVID-19 are increased inflammatory markers such as C-reactive protein, ferritin, erythrocyte sedimentation rate, Interleukin-6 (IL-6), and lymphocytopenia, among others.[12] COVID-19 has posed tough challenges for healthcare workers because of the absence of effective and proven treatment. COVID-19 has a high case fatality rate of 4.5% among patients older than 60 years.[13] As a result, various antiviral and anti-inflammatory medications such as hydroxychloroquine, remdesivir, monoclonal antibodies, and convalescent serum are being used on a compassionate basis in patients with severe COVID-19.[14-16] Currently treatment of severe COVID-19 with antiviral therapy such as remdesivir, hydroxychloroquine, lopinavir, ritonavir, or any other antiviral agents along with supportive treatment is considered as the standard of care (SOC).

Recently convalescent serum from patients who recovered from COVID 19 has been used in the treatment of severe disease.[17] In a randomized clinical trial (Total n=103, study group n=51, control group n=52) with COVID 19, there was no significant difference in 28-day mortality or improvement in the severity of the disease [Hazard ratio 1.40 [95% CI, 0.79-2.49]; $P = .26$). However, among patients with severe COVID 19, there was a significant improvement in respiratory status and mortality when compared to the control group (hazard ratio, 2.15 [95% CI 1.07-4.32] $P = .03$).

ARDS is characterized by inflammatory cytokine release syndrome, among which IL-6 has a pivotal role.[18] IL-6 is one of the significant inflammatory markers released during the cytokine storm due to COVID-19.[19]. Tocilizumab (TCZ) has been proposed as one of the potential treatments in patients with severe COVID-19 due to its ability to block IL-6-mediated inflammatory response. TCZ is an anti-IL-6 monoclonal antibody previously used in the treatment of rheumatoid arthritis and giant cell arteritis.[20] Various single-arm non-randomized studies have evaluated the effect of TCZ in severe COVID-19 and claimed a notable improvement in the clinical condition of these patients.[16, 21] Table 1 lists currently published single-arm studies that evaluated TCZ in the treatment of severe COVID-19. Several randomized controlled trials (RCTs) are currently being conducted to evaluate the efficacy of TCZ in COVID-19.[22, 23] In this article, we performed a systematic review and meta-analysis of studies that compared the role of TCZ on mortality in severe COVID-19 as compared to the SOC.

MATERIALS AND METHODS:

This meta-analysis was performed in accordance with Preferred reporting items for systematic review and meta-analysis statement (PRISMA).[24]

Definitions:

I. **Severe COVID-19**: Patients with respiratory rate ≥ 30 breaths/min, or peripheral capillary oxygen saturation ≤ 93% or PaO2/FiO2<=300 mmHg, or combination of these findings.

II. **Critical COVID-19**: Patients with confirmed COVID-19 who required intensive care unit (ICU) management due to mechanical ventilation or sepsis management

III. **Standard of care** (Control group): Patients with confirmed COIVD-19 were treated with any combination of the following treatment options; supplementary oxygen, antiviral agents (Remdesivir, Lopinavir/Ritonavir, Darunavir/Cobicistat), antimalarial agents (Hydroxychloroquine), anti-inflammatory agents such as steroids, and antibiotics (Azithromycin)

IV. **Tocilizumab group:** Patients were treated with TCZ in addition to SOC

Patients, intervention, comparison, and outcomes (PICO) questions:

Patients: Patients admitted to hospitals with a confirmed diagnosis of COVID-19

Intervention: Evaluation of TCZ in the treatment of severe COVID-19

Comparison: TCZ and SOC in the treatment of severe COVID-19

Outcome: Reduction in all-cause mortality

Search strategy:

An electronic database literature search for studies that compared 'TCZ and SOC' for the treatment of COVID-19 was performed on PubMed, Embase, Cochrane library, Web of Science, and MedRxiv for articles published from December 2019 till June 14th, 2020. Search words 'Tocilizumab,' 'anti-interleukin-6 antibody,' and 'COVID-19' or 'coronavirus 2019' in various combinations.

Study selection criteria:

We included clinical studies that reported mortality data in severe COVID-19 patients that were treated with TCZ. The primary outcome of interest was mortality in severe COVID-19. Only studies that compared mortality rates of patients who received TCZ and SOC were included in the meta-analysis. The articles, which were in the form of only abstracts, letters without original data, case reports, reviews, meta-analysis, animal studies, or studies that did not report original data on both TCZ and SOC groups, were excluded. Further attempts were made to identify relevant studies through references to find eligible studies.

Data extraction:

Initial data collection was done by two independent investigators (UB and KN) who imported the data onto a standardized excel sheet. When there was no consensus on the eligibility of the studies, a senior author

(HG) reviewed the study independently, and the final decision was made regarding inclusion or exclusion of the study. The following data were extracted from each study; authors' names, country, type of study, number of patients in SOC and TCZ groups, patients' gender, age, drugs used in standard of care, and mortality in both groups.

Quality assessment: The quality of the included studies was assessed using the Cochrane risk of the bias assessment tool. Quality assessment and scoring of each included studies that were performed based on the selection of study groups, compatibility, and assessment of outcomes.

Outcomes:

The primary outcome of interest was mortality in severe COVID-19 patients in those who received SOC versus TCZ. Sensitivity analysis was performed to evaluate the effect of each study on the pooled estimates by the exclusion of one study at a time. Any significant change in pooled estimates was reported. We also performed a sensitivity analysis for studies from Europe and the USA, retrospective versus prospective studies, and studies that used antiviral medications versus those which did not. Sensitivity analysis was also done to evaluate the difference in primary endpoints when steroid was used in the SOC.

Statistical analysis:

The data extracted from studies found on online databases, including PubMed, Embase, Cochrane library, and web of science, were peer-reviewed. Studies that were retrieved from medRxiv were not peer-reviewed, and analysis performed on these studies was considered exploratory. The primary outcome of interest was pooled all-cause mortality in severe COVID-19. The pooled estimates with a 95% confidence interval (CI) were synthesized by meta-analysis using the 'DerSimonian-Laird random-effects model.' Heterogeneity across the included studies was performed using inconsistency index I_2. The heterogeneity was classified as low, moderate, and substantial heterogeneity, when the inconsistency index was 25%, 50%, and 75%, respectively. The publication bias was assessed using funnel plot analysis and Egger's test. Statistical

analysis was done using Review Manager (Version 5.3; The Nordic Cochrane Centre, Copenhagen, Denmark) and STATA 14.2 (StataCorp. 4905 Lakeway Drive, College Station, Texas 77845 USA).

RESULTS:

Study characteristics:

A total of 693 studies were identified through an initial literature search. After exclusion of duplicates and screening of articles based on the title and abstract, 51 articles remained. These articles were further reviewed thoroughly, and finally, sixteen studies were eligible for the primary outcome. There were thirteen retrospective studies[25-37] and three prospective studies.[38-40] **Figure 1** provides details of the literature search and study selection process.

There were a total of 3,641 patients with more than 2,283 males from sixteen included studies. The majority of the patients were males (68.3%). There were 2,488 patients in the SOC group and 1,153 patients in the TCZ group. All patients included in the meta-analysis received SOC, and the TCZ group received Tocilizumab in addition to SOC. Hydroxychloroquine was used in all the included studies, Azithromycin was used in 6 studies, Lopinavir/Ritonavir combination was used in 6 studies, steroids were used in 12 studies, Darunavir and Cobicistat combination was used in 3 studies, and remdesivir was used in 2 studies. **Table 2** lists the studies included in the meta-analysis and study characteristics.

Primary outcome and sensitivity analysis:

The mortality rate of COVID-19 patients in the TCZ group was 22.4% (258/1153), and the mortality rate in the SOC group was 26.21% (652/2488). The pooled odds ratio was 0.57 (95% CI 0.36-0.92; p=0.02). Forest plot analysis of the primary outcome is shown in **Figure 2.** There was substantial heterogeneity among the included studies (I_2=80%).

Sensitivity analysis by the exclusion of each study at a time showed no significant difference except when Capra et al.[26] excluded; loss of statistical significance was observed (Pooled OR 0.65 [95% CI 0.42-1.01] p=0.060). Sensitivity analysis of retrospective and prospective studies showed pooled OR 0.57 (95%CI 0.33-0.99; p=0.05), and pooled OR 0.53 (95% CI 0.26-01.09; p=0.08), respectively. **Figure 3** shows forest plot analysis for the pooled estimations of retrospective and prospective studies. Sensitivity analysis of studies that used steroid as SOC and those did not show a pooled OR 0.76 [95% CI 0.47, 1.23; p=0.27] and pooled OR 0.24 [95% CI; 0.10-0.54, p<0.01], respectively. **Figure 4** shows the forest plot analysis of sensitivity analysis for the use of steroids in the included studies. Further, sensitivity analysis of studies from Europe and USA showed pooled OR 0.52 [0.23, 1.17; p=0.12] and pooled OR 0.61 [0.46, 0.79; p<0.01], respectively. Quality assessment of included studies was done using the Cochrane risk of bias tool with parameters for each study is shown in **Supplementary Table 1.**

Publication bias:

Analysis of publication bias using the funnel plot showed the clustering of studies towards the peak and median (**Supplementary Figure 1**). There were four studies that were outside of the funnel. Further analysis using Egger's test (p = 0.087) and Begg's test (Z =0.09) suggested no significant publication bias.

DISCUSSION:

In this meta-analysis including 3,641 patients, TCZ (11.9%) group had 3.81% less number of deaths when compared to SOC (n=16; pooled OR 0.57 [95% CI 0.36-0.92] p=0.02). The analysis also showed that, when steroids are used in the treatment of severe COVID-19, there was no statistical difference in mortality between TCZ and SOC (n=12; pooled OR 0.76 [95% CI 0.47, 1.23; p=0.27). However, when steroid was not used TCZ group had significantly low mortality when compared to the SOC group (n=4; pooled OR 0.24 [95% CI; 0.10-0.54] p<0.01). Sensitivity analysis showed that mortality trends in prospective studies suggest TCZ group did not show a significant difference when compared to SOC (n=3; pooled OR 0.53

(95% CI 0.26-01.09; p=0.08). This is likely due to a lack of power since there were only three studies with the small study population. Possible reasons for substantial heterogeneity among the studies included in the meta-analysis (I_2=80%) are; the difference in the age and comorbidities, variability in the follow-up period, and definition of death due to COVID-19, and response to treatment.

Our meta-analysis shows that the addition of TCZ might significantly reduce mortality in severe COVID-19. However, when steroids are used in the standard of care, the absence of a significant difference in mortality suggests possible role anti-inflammatory properties of steroids in the treatment of severe COVID-19. It was also observed that studies from Europe showed no significant difference in mortality between the TCZ group and the SOC group (n=10; pooled OR 0.52 [95% CI 0.23-1.17] p=0.12). However, Studies from the USA did show lower mortality in the TCZ group when compared to SOC (n=6; pooled OR 0.61 [95% CI 0.46-0.79] p<0.01). This could be related to an acute shortage of ICU beds in Italy and a rapid rise in COVID-19 cases in Italy since most of the European studies were from Italy. This also highlights the availability of resources can significantly affect the outcomes.

SARS-CoV-2, the causative organism of COVID-19, commonly enters the human body through inhalation of droplets. Once the virus comes in contact with respiratory mucosa, the spike (S) protein on the viral cell membrane fuses with the angiotensin-converting enzymes 2 (ACE2) receptors expressed on the mucosal cells, and the viral RNA enters the cell.[41] These infected cells undergo apoptotic changes and phagocytosed by macrophages and presented to antigen-presenting T cells, which in turn leads to CD4 T cell-dependent immune response and results in increased antibody production from B lymphocytes. Ultimately, the unrestricted release of inflammatory cytokines from the immune response leads to ‘cytokine release syndrome’ (CRS). Patients with severe COVID-19 have been shown to have lymphocytopenia and increased plasma concentration of pro-inflammatory cytokines such as IL6, interleukin 10, granulocyte stimulating factor (G-CSF), monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor (TNF).[42]

The role of TCZ in the treatment of COVID-19 is hypothesized based on its ability to block IL 6 activity, a pro-inflammatory cytokine that plays a significant role in the development of ARDS. In a prospective single-arm observational study by Xu et al., twenty-one patients were treated with TCZ. At the end of 5 days, there was a significant improvement in the inflammatory level of markers, lymphocytopenia, and interstitial lung changes—oxygen requirement reduced in all of the patients. None of the patients died.[43] In another prospective single-arm study by Toniati et al., 100 patients with critically ill COVID-19 patients requiring mechanical ventilation were treated with TCZ. At the end of 10 days follow up, 77% of patients experienced significant improvement in respiratory condition and clearing of bilateral interstitial opacities on chest X-ray. The study showed overall mortality of 20%. In another single-arm observational study, 63 hospitalized patients with COVID-19 treated with TCZ also had improvement in oxygen requirement, with an increased likelihood of survival (Hazard ratio 2.2; 95%CI 1.3, 6.7; $p<0.05$) and 11% overall mortality. Several other studies showed that TCZ might have a beneficial effect in the treatment of COVID-19 in organ transplant recipients.[44-46] Based on these encouraging results, several RCTs are underway to evaluate the efficacy of TCZ in COVID-19.

Although our study shows that there is no clear evidence to show the superiority of TCZ over SOC, nearly 45% less death in the TCZ group suggests possible benefit in reducing the mortality in severe COVID 19. Future studies should consider evaluating TCZ against SOC and convalescent serum in the management of severe COVID 19. It is also important to note that TCZ may have a supporting role in combination with SOC, and this needs to be explored as well.

Our study has a few limitations that need to be noted; most of the included studies are retrospective observational studies with only three prospective studies. Most of the included studies were from Italy and the United States. Therefore, the results may not be generalizable. The risk of selection bias is high since most studies did not report whether patients included in the study were consecutive. We were unable to estimate the effect of resource shortage or availability on mortality since there was a reported shortage of intensive care units to provide appropriate care for severe COVID-19 patients in Italy. Some of the severe

COVID-19 patients were treated in the general ward. Mortality can be significantly affected by comorbidities, which is not evaluated in our meta-analysis. This may have played a role in patient mortality and, therefore, might have affected the outcomes. Also, we were unable to determine which patients would benefit from TCZ and which patients do not. Lastly, pooled analysis with studies with substantial heterogeneity is debatable. Large RCTs with sufficient power to evaluate the effectiveness of TCZ in the treatment of COVID-19 are needed. Also, there appears to be a role for steroids in the treatment of severe COVID-19. Future studies should evaluate TCZ versus steroids in treating severe COVID patients in randomized clinical trials.

In conclusion, this systematic review and meta-analysis summarize that the addition of TCZ to SOC may reduce the mortality in severe COVID-19. With no definitive treatment available, TCZ might be a choice in the treatment of severe COVID-19. Large, high-quality prospective studies and RCTs are urgently needed to evaluate the role of TCZ in the treatment of severe COVID-19.

References:

[1] Bogoch, II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med. 2020;27.

[2] Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214-7.

[3] World health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. WHO; 2020.

[4] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet: Lancet Publishing Group; 2020. p. 497-506.

[5] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.

[6] Li X, Zai J, Wang X, Li Y. Potential of large “first generation” human-to-human transmission of 2019-nCoV. Journal of Medical Virology. 2020;92:448-54.

[7] Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? The Lancet Gastroenterology & Hepatology. 2020;5:335-7.

[8] Perisetti A, Gajendran M, Boregowda U, Bansal P, Goyal H. COVID-19 and gastrointestinal endoscopies: Current insights and emergent strategies. Digestive Endoscopy. 2020.

[9] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation. 2020;130:2620-9.

[10] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. Journal of Hepatology. 2020.

[11] Kopel J, Perisetti A, Gajendran M, Boregowda U, Goyal H. Clinical Insights into the Gastrointestinal Manifestations of COVID-19. Dig Dis Sci. 2020;65:1932-9.

[12] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020;8:420-2.

[13] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious Diseases. 2020;20:669-77.

[14] Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384.

[15] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395:1569-78.

[16] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92:814-8.

[17] Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020.

[18] PARK WY, GOODMAN RB, STEINBERG KP, RUZINSKI JT, FRANK RADELLA I, PARK DR, et al. Cytokine Balance in the Lungs of Patients with Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine. 2001;164:1896-903.

[19] Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. Journal of Medical Virology. 2020.

[20] Venkiteshwaran A. Tocilizumab. 2009;1:432-8.

[21] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America. 2020;117:10970-5.

[22] Rilinger J, Kern WV, Duerschmied D, Supady A, Bode C, Staudacher DL, et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:470.

[23] Maes B, Bosteels C, De Leeuw E, Declercq J, Van Damme K, Delporte A, et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:468.

[24] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine. 2009;6:e1000097.

[25] Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43-9.

[26] Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31-5.

[27] Moreno Garcia E, Rico Caballero V, Albiach L, Aguero D, Ambrosioni J, Bodro M, et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv. 2020:2020.06.05.20113738.

[28] Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology. 2020.

[29] Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. medRxiv. 2020:2020.05.21.20109207.

[30] Kewan T, Covut F, Al–Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine. 2020.

[31] Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020.

[32] Martinez-Sanz J, Muriel A, Ron R, Herrera S, Ron R, Perez-Molina JA, et al. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study. medRxiv. 2020:2020.06.08.20125245.

[33] Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020:104444.

[34] Ramaswamy M, Mannam P, Comer R, Sinclair E, McQuaid DB, Schmidt ML. Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study. medRxiv. 2020:2020.05.14.20099234.

[35] Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study. QJM: An International Journal of Medicine. 2020.

[36] Roumier M, Paule R, Groh M, Vallee A, Ackermann F. Interleukin-6 blockade for severe COVID-19. medRxiv. 2020:2020.04.20.20061861.

[37] Wadud N, Ahmed N, Mannu Shergil M, Khan M, Krishna MG, Gilani A, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. medRxiv. 2020:2020.05.13.20100081.

[38] Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8:695.

[39] Mikulska M, Nicolini LA, Signori A, Di Biagio A, Sepulcri C, Russo C, et al. Tocilizumab and steroid treatment in patients with severe Covid-19 pneumonia. medRxiv. 2020:2020.06.22.20133413.

[40] Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv. 2020:2020.05.29.20117358.

[41] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395:565-74.

[42] Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

[43] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020:202005615.

[44] Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter. Am J Transplant. 2020.

[45] Fontana F, Alfano G, Mori G, Amurri A, Lorenzo T, Ballestri M, et al. Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine. American Journal of Transplantation. 2020.

[46] Lauterio A, Valsecchi M, Santambrogio S, De Carlis R, Merli M, Calini A, et al. Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab. Transpl Infect Dis. 2020:e13334.

[47] Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020.

[48] Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney International. 2020.

[49] Borku Uysal B, Ikitimur H, Yavuzer S, Ikitimur B, Uysal H, Islamoglu MS, et al. "Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients". J Med Virol. 2020.

[50] Hassoun A, Thottacherry ED, Muklewicz J, Aziz QU, Edwards J. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. J Clin Virol. 2020;128:104443.

[51] Marfella R, Paolisso P, Sardu C, Bergamaschi L, D'Angelo EC, Barbieri M, et al. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab. 2020.

[52] Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36-42.

[53] Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020;38:529-32.

Table 1. Characteristics of single-arm studies evaluating Tocilizumab in COVID 19 patients:

Author, Month, Year	Country	Type of study	Patients n (males)	Age in years (Meam ±SD or median with range)	Comorbidities	Severity	Treatment	Mortality in %
Alattar, April 2020[47]	Qatar	Retrospective	25 (23)	58 (50-63)	Diabetes-48% CKD 16% Cardiac 12%	Critical 100%	TCZ±H, L/R, R*	12%
Alberici, April 2020[48]	Italy	Retrospective	20 (16)	59 (51-64)	Renal transplant patients	Severe 13% Critical - none	TCZ +/- H	25%
Uysal June 2020[49]	Turkey	Retrospective	12 (6)	65±11.3	Diabetes 58% Hypertension 58%	Severe 83% Critical 17%	TCZ+H, O	0%
Hassoun July 2020[50]	USA	Retrospective	9 (6)	60 (37-88)	Diabetes 11% Hypertension 44%Cardiac 11% Obesity 33%	Severe 55% Critical 44%	TCZ + corticosteroids	22%
Luo, March 2020[16]	China	Retrospective	15 (12)	73 (62-80)	Diabetes 26% Hypertension 60%	Severe 40% Critical 46.7%	TCZ+methyl prednisolone	20%
Marfella, May 2020[51]	Italy	Retrospective	78 (55)	65.7 ±13.4	Hyperglycemia (39.7%)	NA	TCZ	NA
Morena, May 2020[52]	Italy	Prospective	51 (40)	60 (50-70)	Cardiovascular diseases 49% Hypertension 29.4% Diabetes 11.9%	Severe 88% Critical – 11.7%	TCZ ±H, L/R, R	27%
Sciascia, May,	Italy	Prospective	63 (56)	62.6±12.5	NA	Severe 100%	TCZ	11%

2020[53]								
Toniati, July 2020	Italy	Prospective	100 (88)	62 (57–71)	Diabetes 17% Hypertension 46% CKD 11% COPD 9%	Severe 57% Critical 43%	TCZ	20%
Xu, April 2020[43]	China	Retrospective	21 (18)	56.8 ± 16.5 (25–88)	Hypertension 43% Diabetes 23.8% Cardiac 9.5% COPD 4.8%	Severe 81% Critical 19%	TCZ	0%

TCZ: Tocilizumab, H: Hydroxychloroquine, L/R: Lopinavir/Ritonavir, R*: Ribavirin, R: Remdesivir, O: Oseltamivir, SD: Standard Deviation, CKD: Chronic Kidney Disease, NA: Not applicable, COPD: Chronic Obstructive Pulmonary Disease



Supplementary Figure 1: Flow chart of selecting eligible studies for the meta-analysis

Table 2: Characteristics of studies included in the meta-analysis

Author	Country	Type of study	SOC Treatment	Subjects Total	TCZ n	TCZ males	TCZ age Median (range) or mean ± SD	TCZ mortality	SOC total n	SOC males n	SOC age	SOC mortality n
Campochiaro et al.[25]	Italy	Retrospective study	H, L/R	65	32	29	64(53-75)	5	33	27	60(55-75.5)	11
Capra et al.[26]	Italy	Retrospective study	H, L/R	85	62	45	63 (54-73)	2	23	19	70(55-80)	11
Colaneri et al.[29]	Italy	Prospective study	H, Heparin, S	112	21	19	NA	5	91	63	NA	19
Klopfenstein et al.[27]	France	Retrospective study	H, L/R	45	20	NA	76.8 ±11	5	25	NA	70.7 ± 15	12
Quartuccio et al.[28]	Italy	Retrospective study	H, L/R, D/C, S	111	42	33	62·4±11·8	4	69	44	56·2±14·2	0
Roumier et al.	France	Retrospective study case control	S	59	30	24	58.8 (12.4)	3	29	24	71.2 (15.4)	9
Wadud et al.	USA	Retrospective study case control	H,A, S	94	44	NA	55.5	17	50	NA	66	26
Ramaswamy et al.	USA	Retrospective study	H,A, S	86	21	13	63.2 (15.6)	3	65	36	63.8 (15.9)	8
Ip et al.	USA	Retrospective cohort study	H,A, S	547	134	99	62 (53 - 70)	62	413	257	69 (58 - 77)	231
Somers et al.	USA	Prospective study cohort study	H, R*, S	154	78	42	55 ± 14.9	18	76	40	58 ± 14.9	36
Kewan et al.	USA	Retrospective cohort study	H,A, S	51	28	20	62(53-71)	3	23	11	70(55-75)	2
Martinez-Sanz et al.	Spain	Retrospective cohort study	H,A, S, L/R	1229	260	191	65 (55 - 76)	61	969	574	68 (57 - 80)	120
Guaraldi et al.	Italy	Retrospective cohort study	H, L/R, D/C,	544	179	127	64 (54–72)	13	365	232	69 (57–78)	73
Mikulska et al.	Italy	Prospective study cohort study	H, L/R, D/C, S	95	29	24	65.9 (10.2);	6	66	41	73.5 (14.4)	22
Moreno Garcia et al.	Spain	Retrospective study	H,A, S, L/R	171	77	53	61.5 (12.4)	8	94	59	61.4 (16)	17
Rojas-Marte et al.	USA	Retrospective case control study	H,A, S, R*	193	96	74	58.8 6 (13.6)	43	97	63	62.0 6 (14)	55

Legend: H: Hydroxychloroquine, L/R: Lopinavir/Ritonavir, D/C: Darunavir/Covicistat, S: Steroid, A:Azithromycin, R*: Remdesivir, NA: Not available, SOC: Standard of care, TCZ: Tocilizumab

Figure 1: Forest plot comparing patients treated with Tocilizumab and Standard of care by using random-effects model analysis

Study or Subgroup	Tocilizumab Events	Tocilizumab Total	Standar of care Events	Standar of care Total	Weight	Odds Ratio M-H, Random, 95% CI
Campochiaro 2020	5	32	11	33	5.8%	0.37 [0.11, 1.23]
Capra 2020	2	62	11	23	4.4%	0.04 [0.01, 0.19]
Colaneri 2020	5	21	19	91	6.1%	1.18 [0.38, 3.64]
Garcia 2020	8	77	17	94	7.0%	0.53 [0.21, 1.29]
Guaraldi 2020	13	179	73	365	8.0%	0.31 [0.17, 0.58]
Ip 2020	62	134	231	413	8.8%	0.68 [0.46, 1.00]
Kewan 2020	3	28	2	23	3.7%	1.26 [0.19, 8.26]
Klopfenstein 2020	5	20	12	25	5.5%	0.36 [0.10, 1.30]
Martinez-Sanz 2020	61	260	120	969	8.9%	2.17 [1.54, 3.06]
Mikulska 2020	6	29	22	66	6.4%	0.52 [0.19, 1.47]
Quartuccio 2020	4	42	0	69	2.0%	16.25 [0.85, 309.84]
Ramaswamy 2020	3	21	8	65	5.0%	1.19 [0.28, 4.96]
Rojas-Marte 2020	43	96	55	97	8.2%	0.62 [0.35, 1.09]
Roumier 2020	3	30	9	29	5.0%	0.25 [0.06, 1.03]
Somers 2020	18	78	36	76	7.8%	0.33 [0.17, 0.67]
Wadud 2020	17	44	26	50	7.3%	0.58 [0.26, 1.32]
Total (95% CI)		**1153**		**2488**	**100.0%**	**0.57 [0.36, 0.92]**
Total events	258		652			

Heterogeneity: $Tau^2 = 0.61$; $Chi^2 = 75.32$, df = 15 ($P < 0.00001$); $I^2 = 80\%$

Test for overall effect: Z = 2.32 (P = 0.02)



Figure 2: Forest plot for sensitivity analysis of retrospective and prospective studies

Study or Subgroup	Tocilizumab Events	Tocilizumab Total	Standar of care Events	Standar of care Total	Weight	Odds Ratio M-H, Random, 95% CI
1.3.1 Retrospective						
Campochiaro 2020	5	32	11	33	5.8%	0.37 [0.11, 1.23]
Capra 2020	2	62	11	23	4.4%	0.04 [0.01, 0.19]
Garcia 2020	8	77	17	94	7.0%	0.53 [0.21, 1.29]
Guaraldi 2020	13	179	73	365	8.0%	0.31 [0.17, 0.58]
Ip 2020	62	134	231	413	8.8%	0.68 [0.46, 1.00]
Kewan 2020	3	28	2	23	3.7%	1.26 [0.19, 8.26]
Klopfenstein 2020	5	20	12	25	5.5%	0.36 [0.10, 1.30]
Martinez-Sanz 2020	61	260	120	969	8.9%	2.17 [1.54, 3.06]
Quartuccio 2020	4	42	0	69	2.0%	16.25 [0.85, 309.84]
Ramaswamy 2020	3	21	8	65	5.0%	1.19 [0.28, 4.96]
Rojas-Marte 2020	43	96	55	97	8.2%	0.62 [0.35, 1.09]
Roumier 2020	3	30	9	29	5.0%	0.25 [0.06, 1.03]
Wadud 2020	17	44	26	50	7.3%	0.58 [0.26, 1.32]
Subtotal (95% CI)		**1025**		**2255**	**79.7%**	**0.57 [0.33, 0.99]**
Total events	229		575			
Heterogeneity: $Tau^2 = 0.69$; $Chi^2 = 68.09$, df = 12 ($P < 0.00001$); $I^2 = 82\%$						
Test for overall effect: Z = 1.98 (P = 0.05)						
1.3.2 Prospective						
Colaneri 2020	5	21	19	91	6.1%	1.18 [0.38, 3.64]
Mikulska 2020	6	29	22	66	6.4%	0.52 [0.19, 1.47]
Somers 2020	18	78	36	76	7.8%	0.33 [0.17, 0.67]
Subtotal (95% CI)		**128**		**233**	**20.3%**	**0.53 [0.26, 1.09]**
Total events	29		77			
Heterogeneity: $Tau^2 = 0.18$; $Chi^2 = 3.57$, df = 2 ($P = 0.17$); $I^2 = 44\%$						
Test for overall effect: Z = 1.72 (P = 0.08)						
Total (95% CI)		**1153**		**2488**	**100.0%**	**0.57 [0.36, 0.92]**
Total events	258		652			
Heterogeneity: $Tau^2 = 0.61$; $Chi^2 = 75.32$, df = 15 ($P < 0.00001$); $I^2 = 80\%$						
Test for overall effect: Z = 2.32 (P = 0.02)						
Test for subgroup differences: $Chi^2 = 0.03$, df = 1 ($P = 0.86$), $I^2 = 0\%$						



Figure 3: Forest plot for sensitivity analysis of steroid use in SOC (Random-effects model)

Study or Subgroup	Tocilizumab Events	Tocilizumab Total	Standar of care Events	Standar of care Total	Weight	Odds Ratio M-H, Random, 95% CI
1.5.1 Steroid group						
Colaneri 2020	5	21	19	91	6.1%	1.18 [0.38, 3.64]
Garcia 2020	8	77	17	94	7.0%	0.53 [0.21, 1.29]
Ip 2020	62	134	231	413	8.8%	0.68 [0.46, 1.00]
Kewan 2020	3	28	2	23	3.7%	1.26 [0.19, 8.26]
Martinez-Sanz 2020	61	260	120	969	8.9%	2.17 [1.54, 3.06]
Mikulska 2020	6	29	22	66	6.4%	0.52 [0.19, 1.47]
Quartuccio 2020	4	42	0	69	2.0%	16.25 [0.85, 309.84]
Ramaswamy 2020	3	21	8	65	5.0%	1.19 [0.28, 4.96]
Rojas-Marte 2020	43	96	55	97	8.2%	0.62 [0.35, 1.09]
Roumier 2020	3	30	9	29	5.0%	0.25 [0.06, 1.03]
Somers 2020	18	78	36	76	7.8%	0.33 [0.17, 0.67]
Wadud 2020	17	44	26	50	7.3%	0.58 [0.26, 1.32]
Subtotal (95% CI)		**860**		**2042**	**76.2%**	**0.76 [0.47, 1.23]**
Total events	233		545			
Heterogeneity: Tau^2 = 0.46; Chi^2 = 47.42, df = 11 (P < 0.00001); I^2 = 77%						
Test for overall effect: Z = 1.11 (P = 0.27)						
1.5.2 New Subgroup						
Campochiaro 2020	5	32	11	33	5.8%	0.37 [0.11, 1.23]
Capra 2020	2	62	11	23	4.4%	0.04 [0.01, 0.19]
Guaraldi 2020	13	179	73	365	8.0%	0.31 [0.17, 0.58]
Klopfenstein 2020	5	20	12	25	5.5%	0.36 [0.10, 1.30]
Subtotal (95% CI)		**293**		**446**	**23.8%**	**0.24 [0.10, 0.54]**
Total events	25		107			
Heterogeneity: Tau^2 = 0.37; Chi^2 = 6.50, df = 3 (P = 0.09); I^2 = 54%						
Test for overall effect: Z = 3.45 (P = 0.0006)						
Total (95% CI)		**1153**		**2488**	**100.0%**	**0.57 [0.36, 0.92]**
Total events	258		652			
Heterogeneity: Tau^2 = 0.61; Chi^2 = 75.32, df = 15 (P < 0.00001); I^2 = 80%						
Test for overall effect: Z = 2.32 (P = 0.02)						
Test for subgroup differences: Chi^2 = 5.82, df = 1 (P = 0.02), I^2 = 82.8%						



Supplementary Table 1: Cochrane risk of bias table

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Campochiaro 2020	?	+	?	?	+	+	+
Capra 2020	?	+	?	?	+	+	+
Colaneri 2020	?	+	?	?	+	+	+
Garcia 2020	?	+	?	?	+	+	+
Guaraldi 2020	?	+	?	?	+	+	+
Ip 2020	?	+	?	?	+	+	+
Kewan 2020	?	+	?	?	+	+	+
Klopfenstein 2020	?	+	?	?	+	+	+
Martinez-Sanz 2020	?	+	?	?	+	+	+
Mikulska 2020	?	+	?	?	+	+	+
Quartuccio 2020	?	+	?	?	+	+	+
Ramaswamy 2020	?	+	?	?	+	+	+
Rojas-Marte 2020	?	+	?	?	+	+	+
Roumier 2020	?	+	?	?	+	?	+
Somers 2020	?	+	+	?	+	+	+
Wadud 2020	?	+	?	?	+	+	+

Supplementary Figure 1: Funnel plot analysis of publication bias



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	5
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	7
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	9
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	9
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	9
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9-10
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9-10
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	10
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	10

PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	10
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10-11
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	11-12
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	12
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13-14
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	13
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13-15
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	15-17
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	116-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	None

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: **www.prisma-statement.org**.